German Pharma Giant Faces Court Battle Over Kenyan Distribution Deal

A German pharmaceutical manufacturer has found itself embroiled in a High Court dispute after two Kenyan distribution firms accused the company of abruptly cutting off vital medical supplies to major hospitals across the country.

B. Braun Melsungen AG, along with its Kenyan subsidiaries B. Braun Medical Kenya Ltd and B. Braun Pharmaceuticals EPZ Ltd, was taken to court by Ikigai Health Kenya Ltd and Triple Biovitals Limited over alleged breach of distribution agreements. The Kenyan firms claimed the German manufacturer had unlawfully terminated their contracts and withheld critical pharmaceutical products and medical equipment destined for prominent healthcare facilities including Nairobi Hospital, Aga Khan University Hospital, and Kenyatta University Teaching, Referral & Research Hospital.

The distributors, represented by lawyer Philip Nyachoti, painted a picture of severe financial distress and potential public health risks stemming from the supply disruption. They argued that the abrupt termination had not only caused them substantial financial losses but also endangered patient care at the affected hospitals.

However, the case took a complex turn when Justice Josephine Mong’are revealed that the Kenyan firms had acknowledged owing their German supplier a substantial debt of 71 million shillings for previous deliveries. The judge noted this significant financial obligation while weighing the merits of the distributors’ application for an injunction.

In her ruling, Justice Mong’are granted the distributors’ request to block the contract termination, but with stringent conditions attached. The court ordered Ikigai Health Kenya Ltd and Triple Biovitals Limited to pay 31.5 million shillings, representing half of their outstanding debt, before the injunction could take effect.

“I would therefore allow this application by granting the Plaintiffs an injunction as sought by them, but on condition that they make payment of 31,500,000 shillings, being 50 percent of the sums due and owing to the 1st Defendant,” the judge stated in her decision.

The court’s order extends beyond mere payment requirements. Justice Mong’are directed that once the partial payment is made, B. Braun must resume supplies of pharmaceutical products, medical machines, and equipment under the existing agreements. Additionally, the German firm was prohibited from directly approaching hospitals listed as Ikigai’s customers or selling products to them independently.

A particularly urgent aspect of the ruling concerned high-specification medical machines that had been withheld from Jaramogi Oginga Odinga Teaching and Referral Hospital. The court ordered their immediate release and delivery to the facility, highlighting the critical nature of medical equipment in Kenya’s healthcare system.

The dispute also featured allegations of contempt of court against B. Braun officials Torsten Doenhoff and Wycliffe Kiprop. The distributors claimed the company had violated court orders by supplying products directly to Aga Khan Hospital and providing dialysis equipment to JOOTRH. However, Justice Mong’are dismissed these contempt charges after the defendants successfully demonstrated that a demonstration dialysis machine had been delivered to Aga Khan Hospital before they were served with the court order.

The case underscores the delicate balance between commercial obligations and public health needs in Kenya’s pharmaceutical distribution network. While the German manufacturer argued that the Kenyan firms had failed to meet their financial obligations and were not exclusive distributors, the court recognized the broader implications of disrupting medical supply chains.

The ruling serves as a reminder of the critical role that international pharmaceutical partnerships play in Kenya’s healthcare infrastructure, while also highlighting the importance of honoring commercial agreements. The case will likely set a precedent for how similar disputes between foreign suppliers and local distributors are resolved in Kenya’s courts.

With the conditional injunction now in place, the focus shifts to whether the Kenyan distributors can meet the court’s payment deadline and restore the vital supply chain that serves some of the country’s most important medical institutions.​​​​​​​​​​​​​​​​